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Abstract: Infections have been recognized as significant causes of cardiac diseases for many decades. Various 
microorganisms have been implicated in the etiology of these diseases involving all classes of microbial agents. All 
components of the heart structure can be affected by infectious agents, i.e. pericardium, myocardium, endocardium, 
valves, autonomic nervous system, and some evidence of coronary arteries. A new breed of infections have evolved over 
the past three decades involving cardiac implants and this group of cardiac infectious complications will likely continue to 
increase in the future, as more mechanical devices are implanted in the growing ageing population. 
This article will review the progress made in the past decade on understanding the pathobiology of these infectious 
complications of the heart, through advances in genomics and proteomics, as well as potential novel approach for therapy. 
An up-to-date, state-of-the-art review and controversies will be outlined for the following conditions: (i) perimyocarditis; 
(ii) infective endocarditis; (iii) cardiac device infections; (iv) coronary artery disease and potential role of infections. 
INTRODUCTION 
  Infectious agents have long been recognized as causes of 
diseases involving various components of the structure of the 
heart-- pericardium, muscle, endocardium, valves, autonomic 
nerves and more recently the vessels of the heart. The spectra 
of microorganisms causing diseases of the heart are very 
broad and include all classes of microbes-- i.e. viruses, 
bacteria (including myocoplasma, Chlamydia, Rickettsiae 
and mycobacteria), fungi and parasites. 
  The mechanisms by which microbes produce diseases of 
the heart varies with the specific entity, but include direct 
invasion with damage produced by inflammatory reaction 
mediated by cytokines, and chemokines; indirect damage by 
autoimmune mechanisms through molecular mimicry or 
reaction to released and exposed host antigens; and possibly 
through metabolic disturbances that predispose to 
atherogenesis; and the effects of circulating toxins as in 
diphtheria (see Table 1). 
  Much of the advances in the past decade are related to 
refinements in our knowledge of the pathobiology through 
strides in molecular techniques such as advances in 
genomics, proteomics, and use of informatics. These 
advances in our understanding of the pathogenesis of 
diseases have opened new avenues to novel approaches to 
the diagnosis, treatment and prevention. 
PERIMYOCARDITIS 
  Classically, inflammation of the heart lining and muscle 
can present as primarily pericarditis, which is more benign 
and self-limited but often recurrent, or as myocarditis which 
can be asymptomatic and subclinical but on occasion can be 
fulminant with severe heart failure and death. The true 
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incidence of perimyocarditis is unknown and difficult to 
ascertain as most cases are mild and subclinical. Autopsy 
series in unselected subjects have found prevalence of 
inflammation of the myocardium consistent with myocarditis 
in 1 to 9% of routine postmortem examinations [1]. Postmor-
tem studies also found that subclinical myocarditis accounts 
for about 20% of sudden, unexpected deaths in children and 
young adults, including athletes and military recruits [1]. 
  Limited studies have been performed on live patients 
with clinical suspicion of myocarditis or dilated cardio-
myopathy (DCM), using endomyocardial biopsy specimens 
and the Dallas criteria, established in 1986 [2] with proposed 
revision in 1991 [3], for histological evaluation. Limitations 
of endomyocardial biopsies that may affect sensitivity 
include sampling error due to tiny tissue sample, and 
interobserver variation in interpretation of histology. These 
limitations could explain the low incidence of confirmed 
myocarditis (less than 10%) in trials of suspected clinical 
myocarditis [4]. 
  Infectious agents are the leading cause of perimyocarditis 
and probably account for more than 60% of all recognized 
cases. Although in the clinical setting the etiology is mostly 
undefined, it is believed that the majority of “idiopathic 
perimyocarditis” are of viral cause. There are at least 30 
different viruses, 24 bacterial agents, 6 fungi and 7 parasites 
listed as etiology of perimyocarditis [5]. Viral myocarditis 
usually involve diffuse inflammation of the myocardium, 
whereas bacterial and fungal organisms usually cause focal 
myocarditis, secondary to seeding from the blood stream or 
from direct extension of adjacent organs in immuno-
suppression. Moreover, myopericarditis has been repor- 
ted following smallpox vaccination in the US military forces 
[6]. 
VIRAL MYOCARDITIS 
  Viruses are the commonest causes of myocarditis in 
North America and other developed countries, whereas in 
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disease) is the leading cause. The main viruses implicated in 
myocarditis are coxsackie viruses, other enteroviruses, ade-
noviruses, influenza viruses, cytomegaloviruses, and human 
immunodeficiency virus. In a surveillance performed in 
England and Wales between 1990 and 1993, 368 cases of 
myocarditis and/or pericarditis were reported [7]. Viruses 
were reported to cause 69%, bacteria were responsible for 
13%, mycoplasma for 9%, Chlamydia for 4% and 
Mycobacterium tuberculosis for 2%. When restricted to 
myocarditis alone viruses were the etiology in 66% and 
Mycoplasma pneumoniae in 13.5%. Coxsackie B virus has 
been found in most studies to be the commonest viral cause 
of myocarditis, and in the British study [7] it was most 
frequently associated with a mixed picture of perimyo-
carditis, whereas the influenza virus was associated with 
pericarditis or myocarditis alone. 
  Early studies in the nineteen sixties and nineteen 
seventies found that almost 52% of myocarditis occurs in 
children and young adults (<40 years), 14% in those aged 40 
to 59 years, and only 5% in adults over 60 [8], reflecting age 
related susceptibility. Young children and particularly 
infants under 6 months of age, are extremely susceptible to 
enteroviral infections. Other factors that may contribute to 
susceptibility to myocarditis include sex, nutritional status, 
pregnancy and genetic immune-related mechanisms. 
  The clinical presentation of myocarditis may also differ 
with age, as young children more commonly present with a 
febrile, viral-like illness with gastrointestinal and sometimes 
meningeal symptoms with subsequent or concomitant 
cardiac manifestations. The acute form with severe heart 
failure and multi-organ dysfunction is more common in 
neonates and young children, whereas adults usually present 
with subacute smoldering disease and less commonly with 
acute myocarditis [9]. Proving the etiology of myocarditis is 
difficult as standard viral serological and culture methods are 
of low yield, and even molecular methods of endomyo-
cardial – biopsy specimens using polymerase chain reaction 
(PCR) and in situ hybridization may be insensitive because 
of sampling error from a small tissue biopsy. For instance, 
viral genome has been identified in less than 20% of patients 
with DCM [1]. Analysis of large myocardial specimens from 
partial ventrilectomy in 26 patients with DCM have detected 
minus-strand enteroviral RNA indicative of active infection 
in 78% of patients [10]. The only viral sequences detected in 
this group of patients were from Coxsackie B viruses such as 
B3 and B4. In another study of acute myocarditis in children, 
with myocardial tissue samples obtained by different means 
(endomyocardial biopsy, autopsy or from explanted hearts), 
PCR methods detected adenovirus in 15, enteroviruses in 8, 
herpes simplex virus in 2 and cytomegalovirus (CMV) in 
one [11]. A more recent larger study in children and adults 
utilizing multiple (up to nine) endomyocardial biopsies or 
explanted heart samples, analyzed specimens from 773 
patients with acute myocarditis (N=624) and DCM (N=149) 
from 20 centers in the U.S. [12]. Viral genome was 
amplified in 38% of the samples from patients with 
myocarditis and 20% of patients with DCM. Adenovirus was 
identified as the most common virus identified (59.4% of all 
virus detected), with enteroviruses being the second 
commonest viruses in 35.5%, in the myocardium of children 
and adults with myocarditis and DCM. Only adenovirus 
(N=18) and enterovirus (N=12) were detected in DCM. 
Inflammatory changes in the myocardium consistent with 
acute myocarditis were more prominent in enterovirus 
positive cases (79%), compared to adenovirus (40%) which 
were more often mild or borderline myocarditis by the 
“Dallas” criteria. This pattern was also seen in the 
myocardium of DCM, of the 11 patients with inflammatory 
infiltrates, 9 had detectable enterovirus and 2 had 
adenovirus. Dual infection was also found in 26 patient 
samples with myocarditis. In this study control myocardial 
Table 1.  Biologic Mechanisms of Infections on the Heart 
 
Disease  Direct Invasion  Indirect Effect  Autoimmune 
Rheumatic carditis 
(Group A streptococcus) 
- 
+ 
(molecular mimicry) 
+++ 
Pericarditis +  -  - 
Viral Myocarditis 
+ 
 
- ++ 
Chagas disease 
+ 
(early, persistent) 
 
++ 
(late) 
Diphtheria - 
+ 
(toxin) 
- 
Toxic myocarditis 
(Sepsis, toxic shock syndrome) 
- 
+ 
(Excessive inflammatory cytokines, catecholamines) 
- 
Bacterial/fungal myocarditis 
+ 
(focal) 
- - 
Infective endocarditis 
+ 
(biofilm) 
- - 
ICD/Pacemaker infection 
+ 
(biofilm) 
- - Infections in Cardiovascular Disease  Current Cardiology Reviews, 2009, Vol. 5, No. 2     89 
samples rarely demonstrate viral genomes (1.4%) [12]. The 
frequency of adenovirus in the myocardium of patients with 
clinical or subclinical myocarditis may be related to the 
recent identification of a common receptor for Coxsackie B 
viruses and adenoviruses [13].  
  In a further recent study from Germany 245 consecutive 
patients with DCM underwent endomyocardial biopsies with 
PCR analysis for viral genomic sequences [14]. Viral 
genomes could be amplified in 67.4%, the commonest was 
parvovirus B19 (51.4%), human herpes virus-6 in 21.6%, 
enterovirus in 9.4% and adenovirus 1.6%, with 27.3% 
showing mixed viral genomes. Histology did not reveal 
active or borderline myocarditis in any of the samples. These 
data should be interpreted with caution and suggest that 
many of the viral genomes detected may represent non-
specific findings (without causation) and possibly 
contamination from blood or other source. Moreover, this 
study did not include concomitant normal heart tissues for 
controls undergoing PCR analysis. 
  Another recent report has added further murkiness to our 
ranking of specific viruses in the etiology of severe 
myocarditis. In immunosuppressed patients and heart 
transplant recipients, CMV is a common cause of cardiac 
infection but is not considered important in the normal host. 
A recent report from Finland on myocardial autopsy samples 
of 40 patients with fatal myocarditis and 12 controls 
(accidental deaths), describe their findings of viral nuclei 
acids [15]. Viruses were detected in 43% with CMV 
accounting for 15 of the 17 (88%) positives, with 
enteroviruses in only 1 patient and no adenovirus detected. 
Only one of the patient was immunocompromised and in situ 
hybridization assays were positive for CMV DNA in 
cardiomyocytes of 80% of the CMV PCR-positive samples. 
The control samples contained no CMV nuclei acid. The 
importance or relevance of CMV in the myocardium is in 
question as to cause and effect of myocarditis. Previous 
studies of >1100 patients with active or borderline 
myocarditis detected CMV DNA by PCR in only 3% 
(mainly biopsy specimens) [12,16]. 
  How can we resolve these issues of few studies reporting 
viral genomes of atypical agents (not known cardio-
myotropic) in high proportion of cardiac samples from 
subjects with DCM or myocarditis? There are several 
possible explanations for these unexpected reports: i) 
spurious results from false positive PCR, a well known 
problem if extraordinary precautions are not taken to prevent 
contamination; ii) true positive PCR but contamination by 
blood, which may be carrying the virus (i.e. Parvovirus B19 
commonly occurs in children with viraemia and the 
organism is tropic for erythrocytes); iii) detection of latent 
virus that resides permanently in the body after infection (all 
herpes viruses including CMV); iv) reactivation of latent 
herpes viruses (CMV, HHV-6, etc) without causing disease, 
as a result of impaired T-cell function which may occur with 
malnutrition and critical illness (as in severe heart failure); v) 
geographical differences which reflect differences in 
incidence or prevalence of different viruses; vi) variations of 
susceptibility of different populations; vii) variations in 
techniques used for PCR, as most studies used different 
techniques (often “home-brewed”) without national or 
international standardization and verification. Thus, these 
studies with unexpected results need to be verified by several 
other centers with examination of specimens involving larger 
sample sizes. 
  At present enteroviruses, especially Coxsackie B group, 
are the best well studied and proven group of viruses to 
cause significant clinical myocarditis, which has been re-
duplicated in animal models. Coxsackieviruses are 
universally present as human pathogenic enteroviruses in the 
Picornaviridae family. There are two serogroups, A and B, 
with 24 known Coxsackie A serotypes causing mainly 
respiratory and enteric diseases, and 6 known Coxsackie B 
serotypes (1-6) associated with mild to severe diseases of the 
heart, meninges, brain, upper-respiratory tract, liver and 
possibly pancreas [17]. Although all 6 group B serotypes 
have been detected or isolated in patients with heart muscle 
disease, serotype CVB3 has been the most consistently 
reported as the predominant cause of myocarditis, and 
implicated in 20% - 40% of acute myocarditis or DCM [18]. 
  The clinicopathalogical classification of viral myocarditis 
can be defined as: 1) fulminant myocarditis, with severe 
heart failure from left ventricular or biventricular 
dysfunctional (within 3 weeks after onset of viral infection), 
resulting in either death, emergency cardiac transplantation, 
or full recovery; 2) subacute myocarditis with moderate left 
ventricular dysfunction and less distinct symptoms that are 
considered predisposition for DCM; 3) chronic active 
myocarditis, with moderate left ventricular dysfunction and 
indistinct symptoms that precedes or suggest more restrictive 
muscle damage and active scar); 4) chronic persistent 
myocarditis, with normal left ventricular function, but may 
present with sudden death and persistence of inflammation is 
evident on biopsy, and viral genome may be detected [18-
20]. 
  In clinical practice many patients presenting with 
symptoms of acute pericarditis also have myocardial 
involvement, myopericarditis. In a recent prospective cohort 
study of 274 consecutive cases of acute viral or idiopathic 
pericarditis, myopericarditis was found in 40 (14.6%); as 
defined by raised cardiac enzymes or new onset of focal or 
diffuse depressed left ventricular function [21]. Arrhythmia 
was the best predictor of myopericarditis (odds ratio = 17.6), 
and by 12 months normalization of echocardiography and 
treadmill testing occurred in 98% of cases. 
PATHOGENESIS OF VIRAL MYOCARDITIS 
  Experimental murine models of myocarditis utilizing 
Coxsackie virus B3 (CVB3) have demonstrated three distinct 
immunovirological and pathological phases of the disease 
[18,22]. The virus binds to epithelial cells by the membrane 
protein decay accelerating factor (DAF) as the primary 
attachment protein, and the coxsackie virus and adenovirus 
receptor (CAR) as an internalization receptor [18]. The acute 
viraemic phase of the illness is characterized by virus 
replication in blood and infected tissues (especially 
myocardium, spleen and pancreas). In the first 3 to 4 days 
postinfection there is evidence of early cardiomyocyte injury 
with focal dying myofibers (from both necrosis and 
apoptosis) and micro-vesicular vaculation without significant 
inflammation [23]. Once within myocyte the CVB3 produces 
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viral replication and can affect host proteins such as 
dystrophin [24]. Cleavage of dystrophin may have a role in 
release of the virus from myocyte since viral infection is 
increased in the absence of dystrophin. Infection of 
cardiomyocytes stimulate a potent innate immune response 
with release of cytokines interleukin-1 (1L-1), 1L-1, 1L-
6, 1L-18, tumor necrosis factor – (TNF-), TNF-, and 
interferon – (IFN- ) which results in inflammatory cell 
reaction [18]. Appearance of neutralizing antibodies about 
day 4 postinfection may have a role in limiting viral 
replication.  
  The subacute phase of the disease (days 5-14) is heral-
ded by the release of progeny virus in the interstituim, which 
results in considerable increase in lymphocytic infil- 
tration and marked increase in proinflammatory cytokines. 
Natural killer (NK) cells upregulated by 1L-2 then kill 
virus-infected cardiomyocytes to limit virus dissemi- 
nation. However, long term persistence or over-activa- 
tion of NK cells may result in further myocardial damage 
due to excessive release of cytotoxic molecules (i.e. perforin) 
[18]. 
  Between 15 – 90 days postinfection the chronic phase of 
myocarditis usually begins with clearance of the virus from 
blood and peripheral tissues. However, viral RNA and capsid 
protein may still persist in the heart, spleen and lymph nodes 
in mouse and human [25,26]. Persistently infected cells are 
mainly localized within the chronic inflammatory areas, and 
continued viral replication may be responsible for more rapid 
progression of viral myocarditis to heart failure and DCM. In 
humans and murine models during the chronic stage of 
myocarditis the inflammation subsides with increased 
healing, interstitial fibrosis, tissue calcification, ventricular 
dilatation and cardiac hypertrophy development [27]. There 
is evidence of persistent expression of proinflammatory 
cytokine (TNF-), regulatory cytokine 1L-18, and 
immunosuppressive/ fibrinogenic cytokine tumor growth 
factor– in mouse model heart on days 28 and 98 
postinfection, with chronic inflammation as part of the tissue 
healing process [28]. 
  Despite out increased knowledge from studies of the 
murine models of viral myocarditis, the exact mechanisms of 
the pathogenesis still remains somewhat controversial. The 
three main mechanisms proposed for cardiac injury are: 1. 
excessive immune-mediated destruction of the tissue by 
immune cells targeting virus infected cardiomyocytes; 2. 
autoimmune-mediated destruction of cardiomyocytes by 
autoreactive immune cells and/or autoantibodies induced by 
molecular mimicry between viral and host antigenic 
epitopes; and 3. direct virus-induced cardiomyocyte injury 
by cleavage of cellular proteins caused by release of viral 
proteases, that result in impairment of host RNA 
transcription and protein translation [18]. Moreover, the 
virus itself may directly induce apoptosis of the 
cardiomyocytes. Currently, the evidence supports all three 
mechanisms as contributing to myocardial injury and viral 
myocarditis. 
  Unfortunately our greater understanding of the 
pathogenic mechanisms of viral myocarditis and DCM have 
not led to more effective specific therapy. Specific antiviral 
drugs for viral myocarditis are being evaluated and hopes for 
therapeutic success in some patients are now renewed, as 
there are experimental evidences that high viral replication is 
related to severity of disease and that even in the chronic 
phase persistence of virus is associated with pathological 
changes. Two potential antiviral agents with broad spectrum 
activity against enteroviruses, by blocking uncoating of the 
virus, are pleconaril and isoxazoles (WIN54954). Pleconaril 
binds the hydrophobic pocket in viral capsid protein 1, 
inhibiting enteroviral attachment and entry, is still an 
investigational drug which was available on compassionate 
case basis. A few clinical trials in young children with 
enterovirus infections (meningitis and respiratory infections) 
reported decreased severity and duration of symptoms with 
pleconaril [29]. WIN54954, also an experimental antiviral 
drug, reduces mortality in murine CVB-3 myocarditis [30]. 
  There is also evidence that carvedilol, a nonselective 
beta-blocker with additional alphaI-adrenergic blocking and 
antioxidant properties (on the market for years), has been 
shown to be cardioprotective in experimental myocarditis 
[31]. Carvedilol markedly altered myocardial lesions and 
increased IFN- and 1L-12 production on day 7 with 
reduction of myocardial virus replication. Moreover, carve-
dilol demonstrated anti-inflammatory effect and decreased 
toxic oxygen radicals. Selective beta-blocker such as 
metoprolol and a high selective alpha 1-adrenergic blocking 
agent (bunazosin) had no effects in this model [31]. Hence, 
prompt clinical trials with this marketed agent for moderate-
severe viral myocarditis and even DCM are warranted. 
  Other potential novel agents that need further 
investigations (i.e. phase I pharmacology and toxicity 
studies) include a French maritime pine bark extract 
(pycnogenol) which in the murine model was found to 
decrease encephalomyocarditis virus replication and 
suppress expression of proinflammatory cytokines in the 
heart [32].  
CHAGAS MYOCARDITIS 
  T.cruzi, a protozoan parasite, is endemic in most Central 
and South American countries, where it is estimated that 8 to 
10 million people are afflicted with Chagas disease [33]. 
With the increasing immigration from Latin America more 
cases of Chagas disease will be recognized in the United 
States, where it is estimated 100,000 infected persons reside, 
mostly acquired in the endemic areas [34]. Transmission of 
the disease occurs predominantly in the poor rural areas of 
Latin American with the infected triatomine bugs, mainly in 
childhood. However, transmission also occurs through blood 
transfusion (reported in US as well), organ transplantation, 
vertically from mother to infant, and rarely from ingestion of 
contaminated food or drink [34-36]. Rare cases of 
autochthonous transmission have been reported in the US 
[37,38], and T.cruzi infected animals and vectors are found 
in many parts of the US [39,40]. The US food and Drug 
Administration approved a Chagas disease screening assay 
for donated blood at the end of 2006 [41] and by the fall of 
2007 193 donated blood were confirmed positive [33]. 
PATHOGENESIS OF CHAGAS DISEASE 
  Nearly 18 million people in Latin American are infected 
with T.cruzi but only one third progress to chronic Chagas 
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asymptomatic. The asymptomatic individuals are mainly 
responsible for blood and organ transmission. The acute 
phase of Chagas disease is often subclinical and remain 
unrecognized but occasionally patients can present with 
acute myocarditis. The majority of infected patients remain 
in the latent phase of disease for 10 to 30 years or even for 
life, and clinical manifestation (cardiac and digestive forms) 
occur at 2 -3 % every year. 
  The chronic cardiomyopathy of Chagas has been 
considered a paradigm of infection-induced autoimmune 
disease [42], with chronic inflammation and advanced 
cardiac pathology but scarce parasites. Antigen-specific and 
antigen –non-specific mechanisms by which T.cruzi 
infection activate T and B cells, leading to autoimmunity 
have been described [42]. Various T.cruzi  antigens cross 
react with host antigens at the B and T cell level and 
molecular mimicry has been considered as the mechanism 
leading to autoimmunity and pathology of CCC. 
Immunization of these antigens (B13, cruzipain and Cha) 
and / or passive transfer of autoreactive T lymphocytes in 
mice lead to similar disease as found in humans with Chagas 
disease [42].  
  Human CCC is an inflammatory-dilated cardiomyopathy 
with a 2 : 1 predominance of CD8 + cells in relation to CD4 
+ T cells, with a Th1-type cytokine profile, probably 
secondary to local production of 1L-7 and 1L-15 [43]. IFN-  
appears to be the crucial element for parasite control in a 
murine model, as its absence determined a drastic increase in 
parasitaemia, tissue parasitism, leucocyte infiltration of the 
heart and mortality [44]. There is still debate on the issue of 
direct damage caused by the immune response to persistent 
parasites rather than autoimmunity. However, the two 
mechanisms may not be mutually exclusive of each other. In 
A/J mice infection with T.cruzi leads to the development of 
severe inflammation, fibrosis, and parasitosis in the heart 
accompanied by vigorous cardiac myosin-specific delayed 
type hypersensitivity (DTH) and antibody production at 21 
days postinfection [45]. Treatment of infected mice with 
specific antiparasite agent (benznidazole) eliminated 
mortality and decreased disease severity, as well as reduced 
cardiac myosin-specific DTH and antibody production. 
Reinfection of mice with T.cruzi  or immunization with 
myosin led to redevelopment of myosin-specific 
autoimmune response and inflammation. Thus, a direct link 
between the levels of T. cruzi and the presence of 
autoimmunity suggest that parasite elimination may reduce 
or eliminate autoimmunity in the chronic phase of infection 
[45]. 
  Chronic Chagas cardiomyopathy is characterized by 
dilated cardiomyopathy complicated by frequent and 
complex ventricular arrhythmias and conduction defects. In 
patients neurotransmitter receptor autoantibodies (anti-M2 
cholinergic autoantibodies) may contribute to the 
pathogenesis of Chaga’s disease dysautomia but not to 
ventricular dysfunction [46]. In acutely infected rats 
autonomic nerve endings are damaged during T.cruzi-
induced myocarditis, but gradual recovery occurs after the 
acute phase [47]. In chronic infection of mice the hearts 
demonstrate intense inflammation and fibrosis, and decrease 
beta adrenergic and increased muscarinic receptor densities 
than normal controls [48]. 
CLINICAL ASPECTS OF CHAGAS DISEASE 
  Most patients with acute infection of T.cruzi are 
unrecognized or develop mild, nonspecific febrile illness. 
Severe acute myocarditis or meningoenecphalitis are rarely 
detected [33]. The acute phase last about 4 to 8 weeks, and 
then enter the chronic latent phase without symptoms 
(indeterminate Chagas) for life (70 to 80%); and a minority 
(20 to 30%) slowly progress over the years to CCC. Familial 
aggregation of CCC and areas of endemicity indicates 
genetic predisposition for cardiomyopathy. Studies have 
implicated monocyte chemoattractant protein (MCP) – 1 
gene polymorphism [49], HLA class II DRB 1 
polymorphism [50], BAT1 (a putative anti-inflammatory 
gene) variants [51], and IL-1 gene cluster polymorphisms 
[52], as predisposition for Chagas cardiomyopathy. 
  The earliest manifestations of CCC are usually 
conduction system abnormalities (right bundle branch block 
or left anterior fascicular block), and segmentel left 
ventricular wall motion abnormalities; followed later by 
complex ventricular extrasystoles, ventricular tachycardia, 
sinus bradycardia, high degree heart block, thrombo-emboli 
from the heart, and progressive dilated cardiomyopathy with 
congestive heart failure [33]. There are four separate but 
somewhat similar classification schemes to guide presence 
and severity of Chagas cardiomyopathy, including the 
American Heart Association staging [33]. 
  Diagnosis of the acute phase of Chagas disease can be 
made by peripheral blood smear from anticoagulated blood 
or buffy coat, as the level of parasitemia is high and 
trypomastigotes can be detected by microscopy. The 
parasitemia decreases within 90 days of infection 
spontaneously, and is undetectable by microscopy in the 
chronic phase. Diagnosis of chronic Chagas disease is made 
by serology, most often by enzyme linked immunosorbent 
assay (ELISA) and immunofluorescent antibody test (IFA), 
and two tests based on different antigens or technique are 
used in parallel to increase the accuracy of diagnosis [33]. A 
third assay maybe required for discordant results. PCR-based 
methods are more sensitive in the acute phase and variable in 
the chronic phase, but is mostly used as a research tool or for 
examination of cord blood. All children of infected mothers 
should be tested serologically at 9 to 12 months. 
TREATMENT OF CHAGAS DISEASE 
  Benznidazole and nifurtimox are the only proven 
antiparaitic drugs for Chagas disease, both can be obtained in 
the US from CDC under investigational protocols. 
Benznidazole is the preferred agent as it is better tolerated 
and is given orally (5-7mg/kg per day) in 2 divided doses for 
60 days, alternatively nifurtimox (8-10mg/kg per day) in 3 
divided doses for 90 days [33]. The major side effect of 
benznidazole are rashes (30%) with photosensitization, and 
reversible dose-dependent peripheral neuropathy (30%) late 
in the course, gastrointestinal symptoms and rarely bone 
marrow suppression. Nifurtimox adverse effects are more 
frequent and include gastrointestinal complaints in 30-70% 
of patients, central nervous system (CNS) toxicity 
(irritability, insomnia, disorientation and less commonly 
tremors and peripheral neuritis), concurrent alcohol increases 
the risk of adverse effects and should be avoided. Both drugs 
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  Although drug therapy is recommended for all cases of 
acute and congenital infection, reactivated infection (as seen 
with immunosuppression and acquired immunodeficiency 
syndrome), and in children < 18 years with chronic latent 
(indeterminate) infection; generally antitrypanosomal 
therapy should be offered to adults age 19 – 50 years without 
advanced cardiomyopathy. Clinical trials in acute Chagas 
disease with antiparasitic drugs shows parasitological cure in 
60% to 85% of patients, reduction of severity and duration of 
symptoms; and more than 90% parasitilogical cure of 
congenital infection treated within the first year of life [33]. 
  In the chronic phase of Chagas disease (asymptomatic) 2 
randomized, controlled trials of benznidazole in children (6- 
12 years) showed clearance of infection in about 60% 
(seroreversion 3-4 years post-treatment, or reduction in 
xenodiagnosis) [52,53]. Recently, a nonrandomized trial in 
adults with indeterminate and chronic Chagas disease 
without heart failure demonstrated that benznidazole 
(5mg/kg/day) for 30 days, compared to no treatment, was 
associated with reduced progession of heart disease over 17 
years, 12/283 (4%) vs. 40/283 (14%) adjusted hazard ratio, 
0.24, p=0.002 [54]. A RCT is currently underway to assess 
the benefit of benznidazole in patients with mild to moderate 
Chagas cardiomyopathy [55].  
  There is currently no good evidence of the value of 
specific antiparasitic drugs for CCC and many patients are 
treated symptomatically to control heart failure, arrhythmias 
and with anticoagulation to prevent thrombo-emboli based 
on the individual clinical manifestation. The five year 
mortality for CCC with cardiac dysfunction is above 50% 
[56], and risk score for predicting death in Chagas 
cardiomyopathy has been valilated. Six independent 
prognostic factors identified with point score are: 1) New 
York Heart association class III-IV (5 points); 2) evidence of 
cardiomegaly (5 points); 3) left ventricular dysfunction on 
echocardiography (3 points); 4) nonsustained-ventricular 
tachycardia on 24 hour Holter monitoring (3 points); 5) low 
QRS voltage (2 points); and 6) male sex (2 points) [57]. For 
low risk (0 to 6 points) the 10 year mortality was 10%, 
moderate risk (7-11 points) was 44%, and high risk (12 to 20 
points) was 84%. For patients with high risk planned cardiac 
transplantation may be the best option for suitable candidates 
if available. Automatic implantable cardioverter-
defibrillators for those with malignant ventricular arrhythmia 
and recovery from cardiac arrest should be considered [58]. 
Routine use of spiranolactone to block aldoterone is 
probably warranted (as in other dilated cardiomyopathies), as 
in the hamster model spiranolactone attenuated the 
myocardial remodeling in Chagas cardiomyopathy, reduced 
inflammation and mortality during the chronic phase [59]. 
PROGRESS IN INFECTIVE ENDOCARDITIS 
  Infective endocarditis (IE), an uncommon condition, 
despite improvements in diagnostic techniques, surgical 
management and antibiotic choices, still carries a high 
morbidity and mortality. Although the incidence have not 
changed significantly over the past 3 decades, there have 
been changing patterns in the type of microorganisms and 
underlying risk factors [60]. Much of the changing patterns 
of IE is due to improvement in social and economic 
conditions in developed countries, longer life scan and 
invasive methods of management of several diseases, which 
is a price we pay for medical advances. 
  Rheumatic heart diseases is a rare predisposion for IE in 
developed countries for several decades and has been 
supplanted by degenerative mitral and aortic valvular disease 
predisposing to IE, which increases with age and with 
greater predominance in males [60]. However, rheumatic 
carditis still remain common in developing countries. Recent 
prospective observational studies in Europe found that 47% 
of patients with IE had no known previous heart disease 
[61]. This survey conducted in France in 1999 [61] reported 
that prosthetic-valve IE (PVE) was 16% of all cases, but 
more recent European data collected in 2001 indicated that 
PVE was implicated in 26% of IE with 74% affecting native 
valves [62]. 
  Intravenous drug abuses (IVDA) have the highest 
incidence of IE of 1-5% / year [63], followed by patients 
with prosthetic-valves (1-3% after one year, then 0.3 – 0.6% 
per patient year) [64], and in the general population the 
median incidence is 3.6/100,000 persons/year [60]. Noso-
comial infection account for up to 22% of IE with mortality 
greater than 50%, primarily related to long term central 
catheters and surgical procedures (for hemodialysis), with < 
50% having underlying valvular disease [65]. The primary 
pathogens being staphylococci and enterococci with 
mortality above 50%. 
  The microbiology of IE have not changed dramatically 
over the past decade, Staphylococcus aureus is now the 
single commonest organism for native-valve IE (about 34%) 
and PVE (23-30%), followed by oral streptococci (i.e. 
S.viridans) 14-17%, group D streptococci and enterococci 
for native valve IE, and coagulase negative staphylococci 
(CoNS) in PVE (about 17%) [61,62,66]. 
PATHOGENESIS OF IE AND CARDIAC DEVICE 
INFECTION 
  The understanding of the adherence of bacteria to 
damaged or mechanical valves have improved in the past 
decade or more. The major pathogens of IE such as 
Staphylococcus  spp.,  Streptococcus spp., and enterococci 
(accounting for more than 80% of IE) have the greatest 
ability to adhere to damaged valves [64]. Moreover, transient 
bacteremia with these organisms commonly occur with 
normal daily activities. Damaged endothelium and prosthesis 
results in stimulation of tissue factor and other procoagulants 
that results in deposits of coagulum on the valves. The 
coagulum contain large quantities of fibrin-fibrinogen, 
fibronectin, plasma proteins and platelet protein. Pathogens 
associated with IE bind to these proteins, causing 
colonization and proliferation following transient 
bacteremia. In experimental IE S.aureus relies on sequential 
fibrinogen-binding (for valve colonization) and fibronectin-
binding (for endothelial invasion) [67]. In animals, 
fibrinogen-binding (but not fibronectin – binding) was 
associated with induction of endocarditis, but both 
fibrinogen-binding and fibrinonectin-binding were 
associated with disease severity. In cultured cell lines 
fibrinogen- and fibronectin binding act synergistically to 
cause invasion of cells [67]. Adherence of S.aureus  to 
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mediated by microbial surface proteins interaction with host-
tissue ligands, such as FNbp A and B which bind to 
fibronectin; clumping factor which binds to fibrinogen; and 
collagen adhesin which binds to collagen [68,69]. 
  The mechanisms of coagulase negative staphylococci 
(CoNS) infection of cardiac prostheses, including 
pacemaker/defibrillator leads are somewhat different. 
Staphylococcus epidermidis achieve attachment to surfaces 
of devices mediated by nonspecific factors (such as surface 
tension, hydrophobicity, and electrostatic forces) or by 
specific adhesins (proteinaceous autolysin encoded by the alt 
E gene and the capsular polysaccharide adhesin, likely 
encoded by the ica operon) [70,71]. The accumulative phase 
during which the bacteria adhere to each other to form a 
biofilm, is mediated by the polysaccharide intercellular 
adhesin. Significant advances have been made in the past 
decade in understanding the pathobiology of biofilm 
formation. 
    Biofilm is universal for all device related infections 
including those of the heart, and the vegetations of both 
native-valve IE and PVE consist of biofilm colonies [72]. By 
understanding the microbiology of biofilms may lead to 
novel therapeutic advances and prevention of IE and cardiac 
device infections. It certainly explains the need for 
prolonged, intravenous high dose antibioties to achieve cure 
of IE and the universal necessity for removal of infected 
cardiac devices, except for some cases of PVE. A possible 
explanation for our ability to cure many PVE without valve 
replacement, whereas all infected pacemaker and 
defibrillator etc needs to be removed, maybe that the biofilm 
colonies are restricted to the vegetations in PVE but are more 
extensive on the infected surfaces of other cardiac devices. 
  Biofilm is made up of a complex sessile community of 
microbial cells that is irreversibly attached to a substratum 
and to each other, embedded in a matrix of extracellular 
poylmeric substances (slime), and are more metabolically 
active than free floating (planktonic) microorganisms [72]. 
There are several features of biofilm infection that makes 
medical therapy difficult and usually prerequisite removal of 
the foreign body to attain cure. The mechanism of biofilm 
resistance to medical treatment involves local defect in both 
host’s humoral and cellular defences. There is decreased 
opsonic antibody response to the biofilm cell envelope 
proteins, impaired phagocytosis and killing by neutrophils 
[73]. Furthermore, extra-cellular slime substance from 
S.epidermidis can also inhibit lymphocyte activity and 
impair cell mediated function [74]. 
  Moreover, biofilm organisms are inherently resistant to 
antibiotics, disinfectants or germicides compared to 
planktonic bacteria. The concentration of antibiotics required 
to kill biofilm phenotype compared to planktonic phenotype 
varies from 20 fold to 1000 fold higher [75]. The 
mechanisms for biofilm antibiotic resistance are complex 
and include: 1) slow penetration and failure to penetrate 
beyond the surface layers; 2) resistant highly protected 
phenotype state (a cell differentiation similar to spore 
formation); 3) and altered microenvironment with 
concentration gradients of nutrients and metabolic products 
existing across the layers or zones of biofilms [75]. Some 
antibiotics (ie aminoglycosides) with positive charge bind to 
negatively charged polymers in the biofilm and retard or 
slow the penetration [76]. 
ADVANCES IN DIAGNOSIS OF IE 
  The diagnosis of IE is based on a combination of clinical, 
microbiologic and echocardiographic findings. The Duke 
criteria proposal in 1994 [77] and modified in 2000 [78], has 
been verified worldwide as a useful criteria for diagnosis of 
definite IE, with presence of two major criteria, or one major 
and three minor criteria. The emphasis of these diagnostic 
criteria relies heavily on positive multiple blood cultures 
with usual pathogens, echocardiographic evidence of 
vegetation or abscess, and predisposing cardiac valvular 
disease. The modified criteria no longer includes visible 
suspicious lesions for vegetations on echocardiography as a 
minor criteria, and Q-fever serology indicative of chronic 
infection has been included as a major criteria. 
  Echocardiography has been used as an important 
diagnostic tool in the evaluation of IE for over 25 years. 
Standard transthoracic echocardiography (TTE) was found to 
be insensitive to detect vegetations (around 50%), and 
transesophageal echocardiography (TEE) was shown to be 
significantly superior to detect vegetations in suspected IE 
more than a decade ago [79,80]. The vegetation size also 
affects the sensitivity of a TTE since only 25% of 
vegetations <5mm and 70% of those between 6-10mm are 
identified [80]. More recently, technological advances have 
resulted in improvements in TTE image quality, especially 
with harmonic imaging. In a relatively recent study 50 
patients with native-valve IE were evaluated by both TTE 
and TEE examinations by high-end machines [81]. The 
sensitivity of TTE for vegetations was only 55% when using 
TEE as the “gold standard” where all patients had detectable 
vegetations by this latter technique. In previous studies using 
pathological examination for detection of vegetations the 
sensitivity of TEE was > 90%, whereas the sensitivity of 
TTE was only 58% [79]. The specificity of both imaging 
methods (with vegetation defined as a mass with 
independent motion attached to an endothelial surface) was 
excellent, 92% to 95%. 
  Patients with suspected IE by clinical criteria with a 
normal good quality TTE study are very unlikely to have IE, 
as the standard TTE have very high sensitivity in detecting 
abnormal valves which predispose to IE.  
  Two other relatively small studies have reported their 
experience with different results using harmonic TTE for 
diagnostic evaluation in IE. In one study from Italy 139 
patients underwent evaluation with harmonic TTE, TEE and 
TTE with fundamental imaging for the presence, dimension 
and characteristics of vegetations [82]. Thirty-five patients 
had definite IE. TEE detected vegetations in 33 patients 
(94%), harmonic TTE in 28 (80%), and fundamental 
imaging in 12 (34.2%). Compared to TEE fundamental TTE 
identified only one of seven abscesses (14% sensitivity), and 
harmonic TTE detected two of seven abscesses (28% 
sensitivity). A more recent smaller study of 36 consecutive 
patients, 19 had definite IE by TEE, found the harmonic TTE 
to have a sensitivity for detection of vegetations of 84%, 
specificity of 88%, positive predictive value of 89% and 
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comparative studies are needed to give a final appraisal of 
the value of harmonic TTE in evaluating suspected IE.  
  Based on current knowledge patients suspected of IE 
should be screened with TTE (harmonic), a negative study 
would make IE very unlikely for native valves. Equivocal 
results or prosthetic valves should undergo TEE, if the 
results are negative or not confirmatory then the TEE should 
be repeated in 7 – 10 days for those with high clinical 
suspicion of IE. 
ADVANCES IN MANAGEMENT OF IE 
  There have been no major advances in the management 
of IE in the past decade or more, although updates on 
guidelines have been recently published. Very few small 
randomized controlled trials have been published on the 
treatment of IE, and current guidelines by expert panels of 
various medical societies are based largely on observational 
data, in vitro studies, and animal experiments using rapidity 
and degree of bacterial killing on valves with abbreviated 
therapy rather than outcome. 
  Although diagnostic techniques, antibiotic choices and 
surgical techniques have improved over the past two 
decades, the complications and mortality of IE have not 
substantially changed. It is evident that we need to make 
earlier diagnosis, with specific microbial identification to 
institute early optimal therapy if we hope to improve the 
outcome. It is disappointing and surprising that even in a 
very recent survey only 71% of patients with IE had blood 
cultures taken before antibiotics [62]. Higher mortality and 
morbidity have been attributed to patients with blood culture 
negative IE, and up to 70% of this group are associated with 
prior antibiotics [84]. Thus, any patients with even the 
slightest suspicion of IE should have at least 3 sets of blood 
culture taken at different times (preferably at least an hour 
apart if the patient is not acutely ill or toxic).  
ANTIBIOTIC THERAPY IN STREPTOCOCCAL IE 
  Oral streptococci of the viridans group are still common 
causes of community acquired native-valve IE or remote 
prosthetic-valve IE. Penicillin G intravenously alone for 4 
weeks is still the best choice for fully susceptible strains, and 
the combination of intravenous penicillin combined with 
gentamicin or streptomycin for 2 weeks only is an 
alternative. This latter combination is mainly of benefit to 
shorten the duration of intravenous therapy, but poses greater 
risk for vestibular-ototoxicity and renal impairment. Thus 
patients should be given the option after discussion of the 
risk-benefit ratio.  
  There have been emergence of oral streptococci with 
increasing resistance to penicillin worldwide, with relative 
penicillin resistance defined as minimum inhibitory 
concentration (M1C) > 0.12 ug/ml to 0.5ug/ml, and 
M1C>0.5 ug/ml are considered fully resistant. Updated 
treatment guidelines in 2005 [85] recommend a 4-week 
course of either penicillin or ceftriaxone in combination with 
gentamicin for the initial 2 weeks for native-valve IE with 
relative penicillin resistant streptococci based on expert 
opinion. However, there is paucity of data on this group of 
viridans streptococcal IE. In a recent report from the Mayo 
clinic 29 patients with IE secondary to penicillin-resistant 
viridans streptococci (with penicillin M1C 4.0 ug/ml), were 
identified over the past 38 years (^ 8 cases per decade) [86]. 
IE caused by these resistant strains accounted for only 6% of 
episodes of viridans streptococcal endocarditis with no 
significant increase over nearby four decades. Moreover, 
only 6.2% of the 29 cases (largest series reported) had 
streptococci that were highly resistant to penicillin (M1C > 
2.0 ug/ml). In this series 19 patients had native-valve IE, and 
9 of 10 patients were cured with 2.3 weeks of combined 
aminoglycoside and a penicillin, and after 1983 8 patients 
received an average of 5.1 weeks therapy, either penicillin or 
ceftriaxone plus aminoglycoside for the initial 2 weeks, or 
ceftriaxone monotherapy with cure in 7 patients. Nine of 10 
patients with PVE were cured with 4.1 week regimen of 
either combination regimen or monotherapy with 
vancomycin or ceftriaxone. Thus, although current treatment 
guidelines should be effective, optimal therapy (least toxic 
and cost-effective) is unknown for penicillin resistant oral 
streptococcal IE. It is very likely that ceftriaxone alone 
would be just as successful as combination with an 
aminoglycoside but further trials are needed. 
STAPHYLOCOCCAL IE 
  S. aureus is the leading cause of health-care associated 
IE, early PVE and drug abuse-associated IE, and is 
associated with a high mortality and morbidity for left-sided 
involvement. Right-sided S. aureus IE in predominantly 
IVDA is a much more benign disease with better outcome 
and complications than left-sided S.aureus IE. The cure rates 
of right-sided IE are usually > 90%, whereas left-sided 
S.aureus IE cure rates are about 60 - 65 %. The difficulty in 
maintaining intravenous access and compliance with pro-
longed treatment regimens led to the adoption of shortened 
combination of beta-lactam resistant penicillin (naficillin, 
methicillin, cloxacillin etc) with gentamicin for 2 weeks in 
IVDA with right sided S.aureus IE in the late nineteen 
eighties. In a open study of 50 consecutive cases of 
methicillin-sensitive  S.aureus (MSSA) right-sided IE in 
IVDA managed in San Francisco, 47 (94%) were cured with 
2 weeks of intravenous nafcillin and tobramycin [87]. 
Subsequently many centers world-wide adopted this 
abbreviated regimen as standard therapy for uncomplicated 
right-sided S.aureus IE. However, in the mid-1990 an open 
randomized study from Spain, found that intravenous 
cloxacillin monotherapy for 2 weeks was just as effective as 
combined cloxacillin plus gentamicin for the same period, 
cure rates 34 of 38 (89%) versus 31 of 36 (86%), 
respectively [88]. Thus suggesting that either combined or 
monotherapy with a beta-lactamase resistant penicillin 
should be satisfactory for most cases of uncomplicated 
MSSA right-sided IE. It should be noted that the sample 
sizes of these reports are not large enough to adequately 
detect even a 20% difference in clinical response. 
  However, short-term therapy with vancomycin or 
teichoplanin in combination with gentamicin is not very 
effective for right-sided MSSA IE (60-70%) [89]. There is 
also recent retrospective data that IVDA with MSSA IE who 
received vancomycin had higher infection-related mortality 
than those treated initially with a beta-lactam agent in Detroit 
[90]. These results lend support to the impression that 
vancomycin is inferior to beta-lactam antibiotics for serious 
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  In patients with left-sided MSSA IE the treatment of 
choice should be a beta-lactam agent for 4-6 weeks. 
Although experts and textbooks recommended adding 
gentamicin for 3-5 days initially, there is no proof of 
significant clinical benefit. In a prospective mulitcenter study 
combining gentamicin with nafcillin for the initial 2 weeks 
did not improve outcome or morbidity, but the combination 
resulted in earlier cessation of bacteremia by 1.3 days over 
monotherapy [91]. Since there was greater toxicity with the 
gentamicin some experts and guidelines recommend 
gentamicin for only 3-5 days in fulminant cases of MSSA 
IE. A recent meta-analysis of comparative trials to assess the 
role of aminoglycoside in combination with -lactam agent 
for treatment of IE has been reported [92]. Five comparative 
trials (four randomized) were analyzed, with 4 studies on 
S.aureus  native-valve IE (N=261 patients). There was no 
significant differences between monotherapy and combi-
nation-therapy regarding mortality, treatment success, or 
relapse of IE. Nephrotoxicity was more common with the 
combination of a aminoglycoside than monotherapy, Odds 
Ratio (OR) 1.72, p=0.020 [92]. 
  There is no clinical study addressing the issue of duration 
of antibiotic therapy in MSSA native-valve IE. As a general 
rule 4 weeks intravenous therapy should be adequate for 
uncomplicated cases, but 6 weeks therapy is preferable for 
complicated cases with perivalvular abscess. 
ENTEROCOCCAL IE 
  Traditionally it has been recommended to treat 
enterococcal IE with a combination of high dose penicillin G 
(24 million units/day) or ampicillin with gentamicin for 4-6 
weeks. Vancomycin is an alternative (with gentamicin) for 
patients allergic to penicillin or for Enterococcus faecium 
resistant to penicillin/ampicillin. These recommendations 
were based on earlier case series showing high failure to 
monotherapy, and in vitro studies showing no single 
antibiotic was sufficiently bactericidal for Enterococcus 
species, and limited animal experiments. Combination with 
gentamicin was selected for strains inhibited by <500 ug/ml 
of gentamicin, as synergy with penicillin or vancomycin 
would be predictable. For gentamicin highly resistant strains 
(M1C   500 ug/ml) susceptibility should be done to 
streptomycin (which would produce synergistic killing with 
the penicillin or vancomycin if the organism was inhibited 
by < 1000 ug/ml). 
  A significant problem with this regimen was a high risk 
of gentamicin toxicity (25 – 40%) when administered for 4 
weeks, especially since enterococcal IE occurred most often 
in older patients. A recent prospective observational study on 
the largest reported series of enterococcal IE have challenged 
the need for  4 week of aminoglycoside. A nationwide 
prospective study in Sweden between 1995-1999 identified 
93 cases of enterococcal IE, 11% of 881 definite episode of 
IE [93]. Study patients received a median duration of 
aminoglycoside (in combination with penicillin/ampicillin or 
vancomycin) for 15 days and total antibiotic duration for 42 
days. The overall cure rate was 81% with 16% mortality and 
3% relapse, similar to results from previous studies with 
combination of 4-6 weeks [94]. Thus, the current best 
available data indicate that combination with aminoglycoside 
should be limited for the initial 2 weeks for treatment of 
enterococcal IE to obtain optimal results and reduce 
aminoglycoside toxicity. 
  Patients with enterococcal IE due to gentamicin and 
streptomycin high level resistance strains has been a 
therapeutic challenge. Occasional cases have been reported 
to be successfully treated with prolonged high dose 
ampicillin monotherapy and surgery, but no large series have 
been reported. Although enterococcal species are generally 
resistant to all cephalosporins there have been a few in vitro 
studies and limited animal experiments demonstrating 
synergy with ampicillin-ceftriaxone against enterococci [95]. 
In a small observational study from Spain 21 patients with 
high-level aminoglycoside resistant (HLAR) E. faecalis IE 
and 22 patients with non-HLAR E.faecalis were treated with 
6 weeks of intravenous ampicillin (12g/day) plus ceftriaxone 
(4g/day) with cure rate of 67.4% (29 of 43 patients) [96]. 
Before this regimen be adopted as standard treatment for 
HLAR enterococcal IE, it would be preferable for an 
international multicenter trial be conducted to compare this 
combination to ampicillin alone. It should be noted the cure 
rate was only 52% (11 of 21 patients) in cases of HLAR 
enterococcal IE receiving the antibiotic combination without 
surgery [96]. 
PROSTHETIC VALVE IE (PVE) 
  Recent international prospective observational study, 
involving 61 centers in 28 countries, has identified S.aureus 
(23%) as the most common cause of PVE, followed by 
CoNS (16.9%) from a cohort of 556 cases [97]. The majority 
(71%) occurred within the first year of valve implantation. 
Complications of PVE are common and include heart failure 
(32.8%), stroke (18.2%), intracardiac abscesses (29.7%), 
need for cardiac surgery (48.9%) and in hospital death 
(22.8%) [97], despite standard recommended combination 
therapy. Current guidelines for therapy of staphylococcal 
PVE are based on in vitro studies, animal models with soft 
tissue foreign-body related infections, and from retrospective 
data obtained in the early 1980s. 
  Current guidelines [85] recommend initial triple drug 
regimen ( lactam agent plus gentamicin plus rifamipin) for 
methicillin-sensitive strains of staphylococcal PVE; or 
vancomycin-gentamicin-rifampin for methicillin-resistant 
staphylococcal PVE for a total of 6 weeks. But there is little 
evidence to support these recommendations. In the 1980s 
Karchmer  et al. [98] reported their experience on 75 
episodes of CoNS PVE, 80% of which were methicillin 
resistant (MRSE). Vancomycin monotherapy was only 
effective 3 of 6 cases (50%), vancomycin plus rifampin in 7 
of 8 (87.5%), vancomycin plus gentamicin in 5 of 5 (100%), 
and vancomycin-rifampin-gentamicin in 6 of 8 (85.7%) of 
cases. This data suggest that vancomycin monotherapy is 
inadequate and that vancomycin should be used in 
combination with either gentamicin or rifampin. The 
argument for triple therapy with gentamicin for initial 2 
weeks is to reduce the risk of rifampin-resistant mutants. In a 
prospective randomized small treatment trial of MRSE PVE 
(published in abstract form only) no difference in cure rates 
(78%) was found between dual therapy (vancomycin-
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rifampin), but rifampin resistance developed in 37% of the 
dual-therapy versus none in triple therapy group [99]. In an 
experimental rabbit model of native-valve IE with MRSE, 2 
days of various therapies were analysed: monotherapies 
(vancomycin or gentamicin or rifampin), versus triple 
combination (vancomycin-gentamicin-rifampin) were com-
pared to dual combination (vancomycin-gentamicin, or 
vancomycin-rifampin) [100]. Outcome measures analyzed 
were bacterial load of vegetations (colony forming units/ 
gram [CFU/g]), and sterile vegetations 7 days after therapy. 
The mean log CFU/g vegetation was significantly higher for 
monotherapies 4.5-7.1 log CFU/g (with no sterilization) 
versus vancomycin-gentamicin 3.3 ± 1.3 log CFU/g (1/7 
sterilization); vancomycin-rifampin 2.7 ± 1.2 log CFU/g (2/7 
sterilization), triple combination 2.1 ± 0.2 (5/7 sterilization). 
The triple combination was significantly better for rapidity 
of sterilization of vegetations versus monotherapies or 
vancomycin-gentamicin (p<0.05), but was not significantly 
superior to vancomycin-rifampin dual combination [100]. 
Thus, if triple-therapy is being used for PVE it would be 
prudent to limit the duration of gentamicin for 5-7 days to 
reduce the risk to toxicity as there is no good clinical 
evidence that triple-therapy (vancomycin-gentamicin-
rifampin) for both MRSA or MRSE infections is necessary. 
  There is even less data to support use of triple 
combination (nafcillin-gentamicin-rifampin) for MSSA PVE 
as recommended by guidelines [85]. Unlike MRSA strains of 
MSSA are readily killed by low concentrations of -lactam 
agents. Thus, the use of rifampin as adjunctive therapy for 
severe MSSA infections is controversial. In a recent review 
of the adjunctive use of rifampin for the treatment of severe 
S.aureus infection it was concluded that the in vitro results 
of interactions between rifampin and other antibiotics are 
variable and method dependent and often do not correlate 
with in vivo findings [101]. Animal studies tended to show a 
microbiologic benefit of adjunctive rifampin use, particularly 
in osteomyelitis and infected foreign body soft tissue 
infection models. There has been no valid prosthetic valve IE 
model studied to date. However, clinical studies so far have 
failed to show a benefit of adjunctive therapy with rifampin 
[101], and further multicenter international trials are needed.  
  In a recent retrospective cohort analysis of native-valve 
S.aureus IE 42 cases were treated with addition of rifampin 
(median 20 days) and 42 cases were not (controls) [102]. 
Cases treated with rifampin were more likely to have longer 
duration of bacteremia (5.2 vs. 2.1 days, p=<0.001) and were 
less likely to survive (79.9 vs. 95%, p=0.048) than controls. 
Unrecognized significant drug-drug interactions with 
rifampin occurred frequently (56%), and significant hepatic 
transaminase elevations occurred in 9 cases (21.4%), all of 
whom also had hepatitis C infection [102]. Hence adjunctive 
rifampin for even MSSA PVE is at best of questionable 
benefit, and potentially could be harmful. Currently there is 
no evidence that MSSA PVE should be treated any 
differently from MSSA native-valve IE. As noted earlier 
unlike foreign body soft tissue or bone infections, PVE can 
often be cured with medical therapy alone. Moreover, both 
native-valve IE and PVE epitomize biofilm infections, which 
are represented by the vegetations on the valves. There is 
valid argument (but controversial) that earlier surgical 
intervention should be performed for S.aureus PVE to 
improve outcome. 
SURGICAL THERAPY FOR IE 
  The indications and guidelines for management of IE 
have recently been updated [85]. S.aureus PVE is associated 
with high mortality and morbidity, including valve-ring 
abscess, dehiscence of the valve, embolization and severe 
heart failure. Early cardiac surgery has been advocated for 
these cases before attaining the usual indications for surgery 
to reduce these complications and high mortality. A recent 
retrospective review of S.aureus PVE from the Mayo clinic 
analyzed 55 cases to identify prognostic factors [103]. 
Twenty-three patients were treated medically and 32 patients 
had surgical intervention. Mortality was higher in the 
medically treated versus surgically treated patients (48% vs. 
28%). Multivariate analysis showed that severity of illness 
(American Society of Anaethesiology (ASA) class IV) and 
bioprosthetic valves were independent predictors of 
mortality. Predictors of good outcome for medically treated 
patients included age < 50 years, ASA score III, and without 
cardiac, central nervous system or systemic complications 
[103]. The limitations of this study include retrospective 
collection of data and small sample size. Thus, the improved 
outcome of surgically managed patients could be from 
selection bias. 
  In the largest prospective observation cohort study of 
PVE ever reported (N=556), in hospital mortality for 
S.aureus PVE was still high (44/128 [34.4°]), despite use of 
recommended standard combination of antibiotics and early 
surgical intervention in many cases (48.9%) [97]. The 
strongest predictors of mortality were persistent bacteremia 
(>7 days), heart failure, intracardiac abscess, and stroke. 
Persistent bacteremia is independently associated with 
S.aureus IE. In a recent analysis of 61 S.aureus PVE from 
merged database of an international collaboration early valve 
replacement was not significantly associated with a survival 
benefit (overall mortality 47.5%) but patients who underwent 
early valve replacement for cardiac complications had the 
lowest mortality rate (28.6%) [104]. 
  Since there has been no randomized controlled trial to 
assess the benefit of surgical therapy in general for IE, 
prospensity analyses have been used to control for bias in 
treatment assignment and prognostic imbalance to evaluate 
surgical intervention. Using prospensity analysis surgical 
therapy was significantly associated with lower mortality in 
patients with moderate to severe heart failure in left-sided 
native-valve IE (14% vs. 51%, p= 0.001) [105]. In a cohort 
of 367 patients with PVE using prospensity analysis in 
hospital mortality was similar for patients treated with 
surgery compared to medical therapy (25% vs. 23.4%, 
respectively) [106]. After adjustment for factors related to 
surgical intervention, brain embolism and S.aureus were 
independently associated with mortality, with a trend 
towards benefit with surgery (OR= 0.56, 95 CI 0.23 – 1.36). 
Timing of the survival end-points may have affected the 
outcomes, as in a previous small single center study of 66 
patients with PVE, benefit of surgery was only evident in 
long term follow-up (survival at 10 years was 28% in the 
medically treated patients vs. 58% in those treated surgically) 
p=0.04) [107]. The debate over the need for early surgical 
intervention will remain unresolved until international 
collaboration result in a large randomized, prospective trial 
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PACEMAKER AND CARDIOVERTER-DEFIBRILLA-
TOR INFECTION 
  Permanent pacemakers (PPMS) and implantable 
cardioverter defibrillators (ICD) are increasingly being used 
for the management and prevention of serious cardiac 
rhythm disturbances. In the United States there was a 42% 
increase (from 3.26 per 1000 to 4.64 per 1000) in the cardiac 
device implantation rate among medicare beneficiaries from 
1990 to 1999 [108]. The rate of PPM or ICD infection has 
varied from 0.13% to 19.9% but has increased by 123% over 
the past decade [108]. Several host-and procedure-related 
factors have been reported to increase the risk of infection 
with the devices, including diabetes mellitus, malignancy, 
operator inexperience, advanced age, corticosteroid use, 
anticoagulation, chronic renal failure, recent device 
manipulation and bacteremia from a distant focus of 
infection [109]. In a recent analysis of 29 PPM-related 
infections and 58 controls multivariate logistic regression 
model identified long-term corticosteroids use (OR, 13.90, 
p=0.03;and the use of > 2 pacing leads versus 2 leads (OR, 
5.41, p=0.01) as independent risk factors for infection [110]. 
Preoperative antibiotic prophylaxis had a protective effect in 
reducing PPM infections (OR, 0.087, p= 0.005). 
  In a retrospective population-based cohort study from 
1975 to 2004 in Minnesota, 1524 patients with cardiac 
devices were identified, with a total person-time follow of 
7578 years [111]. The incidence of definite device infection 
was 1.9 per 1000 device years, with pocket infection without 
bacteremia in 1.37 per 1000 device years, and with pocket 
infection and bacteremia or device-related IE in 1.14 per 
1000 device years. Of the 1524 patients from the full cohort, 
1087 were included in the analysis with 6 pocket infections 
without bacteremia and 78 cases of blood stream infection. 
The most common organisms in patients with bacteremia 
were  S.aureus  (28%, of which 40% were MRSA), 
Escherichia coli (27%),  Klebsiella species (9%), 
Enterococcus species (8%), -haemolytic streptococci (8%), 
CoNS (6%), and others. Six (18%) of 33 who had 
echocardiogram had demonstrable vegetations (seen only on 
TEE), present on the lead only in 2 cases, the valves and lead 
in 2 cases, and valves only in another 2 patients. None of the 
episodes of gram-negative bacilli infection were definite 
cardiac device infection, and originated from the urinary 
tract or intraabdominal source [111]. Twelve (54.6%) of 22 
cases of S.aureus bacteremia had definite or possible cardiac 
device infection vs. 3 (12.0%) of 25 cases of gram negative 
bacteria were possible (not proven) device infection 
(p=0.004). The accumulative probability of device infection 
was higher among those with a defibrillator compared to 
those with a pacemaker in this study (p < 0.001). 
  Other studies have reported that generator pocket 
infection is the commonest clinical presentation (up to 83%) 
with cardiac device related IE in only about 10% [110]. 
However, electrode lead IE occurs in less than 1% of PPM or 
ICD implants (0.58 and 0.65%, respectively, in a recent 
study) [112]. Superficial cellulitis of the wound 
(implantation site) usually occur within the first two weeks 
after surgery, usually no drainage is present and blood 
cultures are negative. The infection generally resolve with 
intravenous/oral antibiotics with a narrow spectrum -lactam 
agent [113]. Pocket infection typically develops within the 
first 6 months of the pulse generator or battery-pack 
implantation, or device manipulation. Even though the 
infection may manifest itself several months after 
implantation, there is evidence the organisms (usually of low 
virulence, ie CoNS or diphtheroids) were inoculated at the 
time of surgery [114]. Infection with more virulent 
organisms such as S.aureus usually present much earlier 
after surgery. Pocket infection generally present with local 
findings (erythema, tenderness and /or drainage) and 20% 
may have constitutional symptoms (fever, chills) [114]. Late 
pocket infection after one year of implantation is often 
associated with recent surgical revision, erosion through the 
skin from inadequate fixation and occasionally from 
bacteremia of another source. Pocket infection, unlike 
superficial cellulitis, requires removal of the lead-generator 
plus specific antibiotics (depending on the organisms and 
susceptibility), and a new pacemaker/ICD in a remote 
location after resolution of the local wound infection (if still 
required as determined by repeat electrophysiological study). 
  Pocket infection is believed to be the most common 
factor leading to PPM/ICD endocarditis with the same 
organism (staphylococci mainly), however, up to 60% of 
patients have no focal signs of pocket infection [115]. 
Clinical presentation of these device related IE consist 
mainly of fever, occasionally with pulmonary infiltrates, and 
late onset electrode endocarditis can also result from 
hematogenous seeding of S.aureus, streptococci, enterococci 
and rarely coliforms. In a recent prospective study of 224 
patients suspected of pacing system-related infections S. 
epidermidis accounted for 66.9%, other CoNS for 28.5%; 33 
patients had IE with 30 demonstrating the same organisms 
on blood culture and lead culture [116]. Also 25% of those 
with endocarditis has multiple organisms (>1 strain or 
species of bacteria). For the diagnosis of pacemaker/ICD IE 
the sensitivity of TTE in detecting lead vegetations ranges 
from 22% to 30%, whereas TEE has a sensitivity of up to 
95% [117]. 
  Management of pacemaker/ICD related IE is with 
appropriate intravenous bactericidal agent depending on 
culture and susceptibility results for 4-6 weeks. Removal of 
the entire cardiac device is recommended as observational 
studies showed high failure rate and relapse with medical 
therapy alone. In a previous retrospective case series of 123 
patients with pacemaker/ICD infection only 0.86% of 117 
patients with removal of the entire device had infection 
relapse versus 3 of 6 (50%) without removal of the hardware 
(p=0.03) [118]. In a smaller prospective study of 31 patients 
the only prognostic factor for failure of treatment or 
mortality was the absence of surgical therapy (p<0.0001) 
[119]. Failure to remove infected PPM/ICD has been 
associated with almost 3-fold increased risk of dying (6.7% 
vs. 17.6%) [114]. In a previous review it was found that the 
mortality rate in patients with PPM/ICD IE treated with 
antibiotics alone range from 31% to 66% vs. 13% to 33% 
(mean 18%) in those treated with antibiotics combined with 
removal of the entire device [120]. 
  In patients with PPM/ICD in place for many years the 
electrode can become embedded and fixated by fibroco-
llagenous tissue. Conservative methods for removal of the 
electrode now include “locking stylet” affixed close to the 
distal end of the electrode; telescoping sheath to disrupt 98     Current Cardiology Reviews, 2009, Vol. 5, No. 2  Ignatius W. Fong 
fibrous attachment mechanically; and laser sheath to 
photoablate the fibrous attachment. These techniques result 
in lead extraction of 81% to 93%, but complications 
(including tamponade) can occur in up to 3.3% [121]. 
Patients with removal of the cardiac device should have re-
evaluation to determine need for re-implantation as a 
significant proportion (13% to 50%) may no longer require 
pacing support [122]. Those requiring re-implantation of the 
device should be done at a separate site when the patient is 
afebrile and no longer bacteremic, and with resolution of any 
pocket-site infection. 
  Although antibiotic prophylaxis is commonly used for 
PPM/ICD implantation there is no large randomized trial to 
prove efficacy. In a meta-analysis of 7 randomized trials 
with 2023 patients (new implants or replacements) systemic 
antibiotic prophylaxis (semi-synthetic penicillin or 
cefazolin), appeared to have a consistent protective effect in 
preventing short-term pocket infection, skin erosion or 
bacteremia [123]. 
INFECTION AND ATHEROSCLEROTIC HEART 
DISEASE 
  Up to recently (< 5 years) there was great interest and 
intensive research internationally on infectious agents 
playing a role in atherosclerosis and the complications, such 
as ischaemic heart disease and stroke. As a result of negative 
therapeutic trials showing no benefit of antimicrobials in 
recurrent heart attacks, strokes or death in relatively large, 
mulitcenter, randomized, controlled trials (RCTs) [124-127], 
there has been a dramatic decline in research and medical or 
public interest. Is this justified and have these RCTs disprove 
the theory that some infections can play a role in the 
pathogenesis of ischaemic heart disease? The resounding 
answer is no!  
  The design of the RCTs and several other limitations 
among them leaves the issue unresolved. This is similar to 
negative therapeutic trials recently reported with agents 
specifically aimed to improve HDL cholesterol, despite the 
large body of data that shows that low HDL predispose to 
CAD and high HDL is cardioprotective [128, 129].  
  The recent large RCTs studied patients with known 
CAD, either chronic stable disease or after acute coronary 
syndrome to assess the value of antimicrobials (newer 
macrolides or quinolones) in preventing secondary cardiac 
events. The hypothesis generating these RCTs is that 
Chlamydia pneumoniae (a common respiratory pathogen) 
can precipitate acute cardiac events or play a role in 
destabilizing existing coronary plaques. The assumption of 
these trials is that persistent viable C.pneumoniae exist in 
coronary arteries in patients with significant anti-
C.pneumoniae antibodies and in the majority of patients with 
CAD irrespective of antibodies [125]. 
  Although the concept of infectious diseases as potentially 
playing a role in the pathogenesis of atherosclerotic disease 
has existed for over a century, renewed interest was 
stimulated by epidemiological studies showing association of 
CAD and antibodies to C.pneumoniae in the past 2 decades. 
The strongest association between ischaemic heart disease/ 
stroke and infection exist primarily for C.pneumoniae and 
bacteria causing periodontitis (ie Porphyromonas gingivalis) 
[130]. However, the strength of the association between 
these infections and CAD by clinical and epidemiological 
studies have been mixed and inconsistent. Whereas 
numerous retrospective case-control and cross-sectional 
studies had shown significant association between past 
infection with C.pneumoniae and periodontal pathogens with 
CAD, prospective cohorts and meta-analyses of these studies 
have not confirmed significant correlation or association 
with infection and atherosclerotic heart disease or stroke 
[131,132]. 
  Atherosclerosis the undergoing cause of CAD and stroke, 
is an inflammatory (low grade) disease with pathobiologic 
mechanisms which are common to the host’s responses to 
many chronic infectious diseases. Microbes may potentially 
play a role in the development of CAD at several steps: i) 
initial endothelial vascular injury via direct or indirect 
mechanisms that could initiate atherosclerosis; ii) 
acceleration of early atherosclerosis via local increase in 
LDL and oxidized LDL by cytokines stimulation or by 
predisposing to abnormal lipid profile; iii) precipitation of 
acute events by predisposing to vulnerable plaque or 
activation of the coagulation cascade [131]. 
  The biologic mechanisms by which these infections 
could play a role in atherogenesis are fairly well established 
by in vitro, ex vivo and in vivo (animal models) [131, 132], 
summarized in Table 2. Moreover, numerous studies have 
found evidence of C.pneumoniae in arterial plaques by 
several different techniques (immune histochemistry, in situ 
hybridization, PCR, electron microscopy and cultures) but 
rarely in normal arteries [131]. The mean prevalence of 
C.pneumoniae in atherosclerotic plaques is about 40 -50%, 
and the presence of the organisms in CAD or other arteries 
do not correlate with the standard antibodies measured in 
clinical trials [131, 133]. Hence recent RCTs that determine 
inclusion of patients by anti-chlamydial antibodies or the 
assumption that most patients have chronic persistent 
C.pneumoniae infection are likely to be under-powered. 
  Animal experiments in rabbits have demonstrated that 
C.pneumoniae  can initiate early atherosclerotic changes in 
the aorta without hyperlipidemia [134]. However, the 
majority of animal experiments have demonstrated that 
C.pneumoniae [131] and P.gingivalis can accelerate 
atherosclerosis in the presence of hyperlipidemia [135]. 
Although theoretically these microbes could lead to 
precipitation of acute cardiac events by destabilization of 
plaques through induction of metalloproteinases or 
gelatinase by macrophages [136,137]; or by inducing tissue 
factor to cause or precipitate acute thrombosis (clot) [138], 
no animal models have shown this effect. Thus, the recent 
RCTs were designed to prevent secondary cardiac events (or 
precipitation by chronic C.pneumoniae infection) which 
have never been demonstrated to occur in animal models. 
 Moreover,  although  Muhlestein  et al. [139] showed in 
the rabbit model (fed cholesterol enriched diet) that 
azithromycin (a newer macrolide) could prevent acceleration 
or enhancement of atherosclerosis (when treated 
immediately after infection), delayed treatment has been 
shown to be ineffective in preventing artherosclerotic 
changes [140]. Furthermore, there is evidence that single 
agents (such as azithromycin or ofloxacin) cannot eradicate 
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continuous cell culture model or experimental murine 
pneumonitis model [141, 142]. Hence the antibiotics used in 
the recent RCTs [124-127] are not very effective in 
eradicating C.pneumoniae from tissues in animals or even 
within human monocytes [143]. Thus the negative results 
from these RCTs could be secondary to an ineffective 
regimen. Currently the best choice of agents to eradicate 
persistent chronic infection with C.pneumoniae is unknown 
but may be a combination with rifampin [142]. 
  Other factors that could affect the outcome of these 
negative RCTs include the fact that the majority of patients 
were already receiving optimal therapy, such as selective -
blocker, anti-platelet drugs (ie aspirin) and “statins”. Thus 
making it extremely difficult for any additional therapy to 
show any difference above standard treatment. This also 
applies to lack of benefit seen with HDL-modifying agents. 
Moreover it has been demonstrated in vitro that “statins” can 
inhibit  C.pneumoniae in cell culture and suppress the 
inflammatory or cytokine response to this microbe that may 
be playing a role in atherogenesis [144]. Recent studies 
demonstrate that simvastatin reduces C.pneumoniae-
mediated histone modification and gene expression in 
cultured endothelial cells, thus down regulating cytokine 
production that are important in initiating and accelerating 
atherosclerosis [145]. Furthermore in acute infection of 
swine with C.pneumoniae via the respiratory tract, there is 
impairment of the muscarinic and kinin-related reactivity of 
coronary circulation, which can be prevented by simvastatin 
[146]. 
RECENT ADVANCES IN INFECTIONS AND 
ATHEROSCLEROSIS 
  There has been no significant advances in the last 5 years 
to further establish the relationship between C.pneumoniae 
or P.gingivalis with CAD/stroke in human trials. To further 
establish this relationship would need more specific and 
sensitive diagnostic blood tests that reflects chronic 
persistent infection and correlates well with the presence of 
C.pneumoniae in atheromatous plaques. One potential 
candidate for diagnosis of persistent C.pneumoniae infection 
is a recently developed enzyme immunoassay [EIA] for 
quantification of chlamydial LPS in serum [147]. However, 
combined serological and pathological studies need to be 
performed to confirm the correlation of the cLPS and 
presence of the organisms in atheromatous plaques. Another 
potential candidate diagnostic test is determination of 
chlamydial heat shock protein (cHSP) antibody [148]. 
However, only one small study to date has been performed 
to determine correlation with pathological evidence of 
C.pneumoniae in atheromas [133]. Commercialization of 
Hsp- 60 monoclonal antibody (Genway Biotech) has now 
paved the way for further larger histopathogical-serological 
studies by other centers. This is crucial before undertaking 
any further large prospective epidemiological cohort studies 
or RCTs of any therapeutic agent. 
  A key issue in the hypothesis of C.pneumoniae role in 
atherogenesis is the ability of this microbe to persist 
intracellularly as an aberrant body, which has been mainly 
described in chronic Chlamydia trachomatis infections 
[149]. These persistent aberrant forms are in an arrested state 
in development, non-culturable, and explains the low yield 
of culturing human atheromas for C.pneumoniae [131]. In a 
recent study the presence of aberrant or persistent bodies of 
C.pneumoniae  were demonstrated in human coronary 
atheromas by immuno-gold electron microscopy technique 
[150]. To define the serological responses to C.pneumoniae 
antigens that are associated with persistent infection, another 
recent report described antibody patterns of sera from 
subjects with and without evidence for persistent 
C.pneumoniae  (determined by multiple PCR analysis at 
different times of peripheral blood mononuclear cells and 
vasculatory samples) by using proteomics, combined with 2-
D gel immunoblotting [151]. In this study a unique antibody 
response pattern (by differential reactivity for 12 proteins) 
were found which reflected persistent C.pneumoniae,  and 
was not predicted by the current gold standard for sero-
diagnosis (the immunofluorescence test). The method used 
in this report, however, would be too expensive, time 
consuming and cumbersome to used for large multicenter 
population studies and clinical trials. Thus application of this 
data to produce a simpler, easily performed test would be 
desirable for future investigation. 
  As mentioned previously C.pneumoniae theoretically 
could precipitate acute vascular events by upregulation of 
matrix metalloproteinases (MMP) in coronary atheromas 
leading to vulnerable plaques. A recent study in human 
Table 2.  Pathogenic Mechanisms of Infections on Atherosclerotic Heart Disease 
 
  Chlamydia Pneumoniae  Periodontal Disease 
Initiation 
Endothelial invasion, 
HSP 60-related dysfunction 
Indirect endothelial dysfunction by LPS, cytokines. 
Early 
disease 
Induce foam cells, oxidize LDL in macrophages; induce fatty streaks in rabbits  Induce foam cells, CRP. 
Acceleration  Enhance lipid-induced atheroma: foam cells, lymphocytes, SMC 
proliferation, cytokines, activate NF-kB. 
Enhance lipid-induced atheroma in rodents; upregulate 
activation of NF-kB 
Precipitation 
 MMP, gelatinase; 
apoptosis, necrosis; 
tissue factor, PAI-1 
inflammtion, procoagulation via proteinase activator 
receptor, activiate factor X. 
Data derived from references [131, 132]. 
Abbreviations: Hsp= heat shock protein; LDL = low density lipoprotein; Lps= lipopolysaccharide; CRP= C-reactive protein; SMC= smooth muscle cell; 
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coronary plaque specimens (N=31) demonstrated significant 
association between expression of MMP-9 and the 
intravascular presence of C.pneumoniae [152]. There is also 
experimental evidence in mice that apoptosis of vascular 
smooth cells (VSMC) is responsible for thinning of fibrous 
cap, loss of collagen and matrix with intense inflammation, 
leading to plaque vulnerability (features that predispose to 
plaque rupture, thrombosis and acute ischaemic events) 
[153].  C.pneumoniae  has recently been shown to induce 
apoptosis and necrosis of human coronary artery endothelial 
cells [154], but the organism can also infect human VSMC 
cells [131]. 
  There is no simple blood test to assess periodontal 
disease and dental examination is necessary. There is recent 
data that have shown a direct relationship between 
periodontal microbial burden and subclinical atherosclerosis 
in 657 subjects by measuring mean carotid artery intima-
media thickness [155]. In a recent cross-sectional study of 
3585 participants  40 years old in the National health and 
Nutrition Examination Survey (NHANES) during 1999- 
2002, a significant association was found between perio-
dontal disease and peripheral vascular disease (OR=2.25, 
p<0.05), which remained significant after adjustment for 
other factors [156]. Over the past decade or more there have 
been numerous basic research studies that demonstrated that 
protease-activated receptors are important in the patho-
biology of hemostasis, thrombosis and vascular disease (all 
key elements in atherogenesis) [157]. P.gingivalis has 
recently been shown to activate protease-activated receptor -
2 in the murine model of infection [158], providing further 
biological support for its possible role in atherogenesis. 
  In conclusion the association of infections, particularly 
C.pneumoniae and periodontal disease, with atherosclerosis 
and the complications still is a viable hypothesis with good 
evidence supported by fundamental research. 
FUTURE DIRECTIONS 
  Progress in the understanding of infectious diseases 
affecting the heart has been significant over the past decade. 
Large randomized therapeutic trials, however, have been 
lacking due to the low prevalence and incidence of these 
diseases. Recent international collaboration of several 
reknown centers have reported large perspective obser-
vational data on IE, but it is time for these groups to design 
and perform meaningful RCTs. For the 21
st Century we need 
to derive guidelines based on large randomized trials in IE, 
myocarditis and others rather than on substandard 
observational data. 
  With respect to proving causality between ischemic heart 
disease/stroke and infections, this will be a daunting task for 
a disease with multiple etiologic conditions. Large 
randomized controlled trials should not be performed until 
several prerequisites are fulfilled (re: C.pneumoniae): 1) an 
easily available test that can be applied to large populations 
that is predictive of persistent, chronic infection in 
atheromas; and 2) a proven effective regimen in suitable 
animal models. Finally these therapeutic RCTs should not be 
performed on subjects with established CAD already on 
standard regimens that include statins. Trials should be 
designed in middle-aged population with subclincial disease 
on imaging, not on other treatment, and to follow the 
progress of these atheromas with and without specific 
therapy for C.pneumoniae. It will be difficult to design a 
proper randomized trial for people with periodontal disease 
to offer proper dental care versus no care, as this would be 
unethical. Whether standard dental care versus intensive 
periodontal care is a feasible alternative, depends on 
previous trials showing that intensive periodontal care results 
in better periodontal health and retention of teeth in the long 
term.  
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